CLINICAL TRIALS PROFILE FOR CYTOTEC

All Clinical Trials for CYTOTEC

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00120042 ↗	Optimisation of the Management of Placental Delivery in Second Trimester Pregnancy Interruption	Completed	The University of Western Australia	N/A	2005-02-01	Interruption of a pregnancy after 14 weeks gestation may be required when the fetus is dead, severely malformed or in cases of maternal illness. This process is usually conducted medically in Australia, using the prostaglandin E1 analogue misoprostol. This prostaglandin, although not specifically licensed for use in pregnancy termination, is now a common abortifacient with a lot of accumulated experience both within Australia and internationally. Since 1996, misoprostol, a synthetic prostaglandin, has been used at King Edward Memorial Hospital as the principal agent for second trimester pregnancy termination. This agent is administered vaginally, and in its current form and dosage regimen results in 75-80% of women delivering within 24 hours. As experience with this agent has grown, it has been observed that in approximately 40% of women the placenta is either completely retained or incompletely delivered, necessitating operative removal and an increased potential for maternal blood loss. In this study, it is planned, in a randomized controlled clinical trial, to evaluate three regimens for the management of placental delivery in women undergoing second trimester pregnancy interruption. The primary intention of this study is to develop a third stage management protocol to reduce the incidence of placental retention in second trimester medical pregnancy termination. The secondary aim of this study is to assess the ultrasound appearance of the uterus and its cavity within 24 hours of second trimester pregnancy termination. The ultrasound appearances of the uterus following second trimester pregnancy loss have not been previously investigated in detail. Previous ultrasound studies of the term postpartum uterus have demonstrated a high incidence of echogenic material within the uterine cavity soon after an uncomplicated vaginal delivery. These findings have been of concern as the ultrasound appearances may erroneously imply a need for operative intervention. The investigators wish to ascertain if this high incidence of echogenic tissue presence is also true in the second trimester. Ultrasound is frequently used by clinicians to define placental completeness and the potential requirement for surgical curettage. The data from this single sonographic examination of the uterus will provide baseline data for a planned longitudinal study of uterine appearances following second trimester pregnancy loss and their correlation with clinical symptoms.
NCT00140114 ↗	Sublingual Versus Vaginal Misoprostol for Labor Induction at Term	Completed	American University of Beirut Medical Center	Phase 3	2004-01-01	Misoprostol (Cytotec®) is a synthetic prostaglandin E1 analog that has been marketed in the United States since 1988 as a gastric cytoprotective agent. In contradistinction to prostaglandin E2 preparations (dinoprostone, Prepidil, Cervidil), misoprostol is inexpensive and available in scored tablets that can be broken and inserted vaginally. Despite a focused campaign by the manufacturer to curtail its use in obstetric practice, misoprostol has, over the past several years, gained widespread acceptance as both a labor induction and a cervical ripening agent. Such off-label indication has been endorsed by the American College of Obstetricians and Gynecologists and other medical bodies. Recently, FDA approved a new label for the use of cytotec during pregnancy which removed pregnancy as a contraindication for its use. Vaginal administration seems to be more efficacious than when given orally, although there is the worry of uterine tachysystole and hyperstimulation with vaginal doses > 50-µg. The use of sublingual misoprostol for cervical ripening at term was recently investigated in two studies that compared it to the oral route, on the assumption that the sublingual route would have the higher efficacy of the vaginal route by avoiding the first pass effects of the gastrointestinal and hepatic systems, while having lower hyperstimulation rates by avoiding the direct effects on the cervix. In addition, the sublingual route would combine an easier administration with the added advantage of no restriction of mobility after administration. There has been no previous report in the literature comparing the use of misoprostol given sublingually to that given vaginally for the induction of labor at term. Our aim is to compare efficacy, safety and patient satisfaction with misoprostol given vaginally (the current standard) to that given sublingually.
NCT00141895 ↗	A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Termination for Intrauterine Fetal Death	Terminated	American University of Beirut Medical Center	Phase 3	2004-09-01	Misoprostol (Cytotec®) is a synthetic prostaglandin E1 analog that has been marketed in the United States since 1988 as a gastric cytoprotective agent. Despite a focused campaign by the manufacturer to curtail its use in obstetric practice, misoprostol has, over the past several years, gained widespread acceptance to effect the medical termination of pregnancy in the second trimester, either alone or after pretreatment with mifepristone. The primary reasons for this prompt incorporation into standard practice include its low cost and the lack of stringent storage requirements. Vaginal administration seems to be more efficacious than when given orally. The use of sublingual misoprostol for first trimester abortions has been extensively investigated as evidenced by the large number of publications comparing sublingual to other routes of misoprostol for first trimester pregnancy termination, on the assumption that the sublingual route would have a similar efficacy of the vaginal route. In addition, the sublingual route would combine an easier administration with the added advantage of no restriction of mobility after administration. There has been no previous report in the literature comparing the use of misoprostol given sublingually to that given vaginally for the second trimester termination following intrauterine fetal death. Our aim is to compare efficacy, safety and patient satisfaction with misoprostol given vaginally (the current standard) to that given sublingually.
NCT00200226 ↗	Oral Misoprostol Before Endometrial Biopsy	Completed	Memorial University of Newfoundland	Phase 3	2003-02-01	An endometrial biopsy involves a thin tube being passed through the cervix (opening of the uterus) to obtain a sample of the lining of the uterus. Sometimes there may be discomfort with this procedure especially if the cervix is not dilated or opened. Previous research has suggested that taking a drug called misoprostol may help the cervix to start to dilate or open. This study will see if misoprostol will help open the cervix for an endometrial biopsy, to lessen the discomfort and make the biopsy easier to perform.
NCT00256009 ↗	Treatment of Late Abortion: Evacuatio Uteri or Conservative Treatment	Unknown status	Rigshospitalet, Denmark	Phase 4	1969-12-31	A randomize trial: expectation or evacuatio uteri for the treatment after late abortion
NCT00383942 ↗	Ripening Interventions: Prostaglandins vs EASI Catheter	Terminated	Loyola University	Phase 4	2006-08-31	The primary aim of this randomized clinical trial is to compare the effect of misoprostol vs extra amniotic saline infusion via a catheter (EASI) for cervical ripening on the proportion of patients delivered by cesarean section for fetal intolerance of labor versus vaginal delivery. The primary hypothesis is that patients undergoing cervical ripening with EASI catheter are less likely to undergo cesarean section for fetal intolerance of labor when compared to women who receive misoprostol.

Clinical Trial Conditions for CYTOTEC

Condition Name

Condition Name for CYTOTEC
Intervention	Trials
Postpartum Hemorrhage	6
Pregnancy	5
Labor Induction	5
Cervical Ripening	4

Condition MeSH

Condition MeSH for CYTOTEC
Intervention	Trials
Hemorrhage	22
Postpartum Hemorrhage	12
Abortion, Incomplete	4
Abortion, Spontaneous	4

Clinical Trial Locations for CYTOTEC

Trials by Country

Trials by Country for CYTOTEC
Location	Trials
United States	49
Egypt	15
Israel	7
Netherlands	4
Sweden	4

Trials by US State

Trials by US State for CYTOTEC
Location	Trials
California	7
Texas	6
Massachusetts	5
New York	5
Illinois	4

Clinical Trial Progress for CYTOTEC

Clinical Trial Phase

Clinical Trial Phase for CYTOTEC
Clinical Trial Phase	Trials
Phase 4	35
Phase 3	19
Phase 2/Phase 3	4

Clinical Trial Status

Clinical Trial Status for CYTOTEC
Clinical Trial Phase	Trials
Completed	57
Unknown status	18
Terminated	11

Clinical Trial Sponsors for CYTOTEC

Sponsor Name

Sponsor Name for CYTOTEC
Sponsor	Trials
Gynuity Health Projects	10
Cairo University	7
Ain Shams University	4

Sponsor Type

Sponsor Type for CYTOTEC
Sponsor	Trials
Other	140
Industry	4
U.S. Fed	1

Cytotec (misoprostol) clinical trials update, market analysis, and generic market projections (2025–2035)

Last updated: July 28, 2026

Cytotec is misoprostol, an oral prostaglandin E1 analog used for prevention and treatment of NSAID-associated gastric ulcers and for obstetric indications such as induction of labor and management of missed abortion. The clinical development pipeline for new Cytotec-branded trials is limited because misoprostol is off-patent in major jurisdictions and supply is largely generic-led. Near-term market dynamics are driven by guideline positioning, generic availability, and safety-related prescribing controls rather than novel phase programs.

What is Cytotec (misoprostol) used for, and which indications drive demand?

Cytotec is approved for:

• Prevention of NSAID-induced gastric ulcers in patients at risk.
• Treatment of gastric ulcers associated with NSAID use.
• Obstetric and gynecologic uses in many countries under local labeling frameworks (exact approved scope varies by jurisdiction; in the US, obstetric uses are not part of the Cytotec labeling in the same way as the ulcer indication).

NSAID ulcer prevention: the core commercial indication

• Misoprostol’s commercial anchor remains NSAID gastroprotection, where it competes primarily with proton pump inhibitors (PPIs) such as omeprazole/esomeprazole and H2 blockers.
• Adoption depends on ulcer risk stratification and tolerability. Diarrhea and abdominal cramping are the main limiting adverse effects for misoprostol.

Obstetric and gynecologic use: demand is policy and guideline dependent

• Misoprostol is widely used globally for abortion care and obstetric management because it is heat-stable and can be administered via multiple routes.
• Country-specific regulatory controls and prescribing restrictions shape volume more than brand-specific factors.

What is the clinical trials update for Cytotec (misoprostol) in 2024–2026?

No Cytotec-specific, late-stage (Phase 3/registrational) clinical trial program is identifiable as a primary driver of label expansion in major markets, consistent with misoprostol’s mature status and generic competition.

Clinical research is concentrated in:

• New dosing regimens for obstetric indications (route and schedule optimization).
• Combination protocols and comparative studies versus other uterotonics.
• Formulation and delivery system studies designed to improve tolerability and adherence.
• Real-world evidence (RWE) on persistence, switching, and adverse event rates in NSAID gastroprotection.

Phase 2–3 focus areas seen across misoprostol research

• Reduced GI adverse events via regimen changes and patient selection.
• Obstetric regimens in post-partum hemorrhage prevention and management contexts.
• Comparative effectiveness research versus mifepristone-based pathways where permitted.

Featured snippet: clinical trials “what matters”

• Misoprostol trials in 2024–2026 largely target regimen optimization and comparative effectiveness, not new Cytotec-branded registrational endpoints.

Which companies are developing or commercializing misoprostol after Cytotec, and how does this affect competition?

Cytotec’s market is dominated by:

• Generic manufacturers of misoprostol tablets (ulcer indication) under ANDAs (US) where applicable.
• Global supply chains serving obstetric and gynecologic use where generics are the practical default.

Competitive implications

• Brand differentiation for Cytotec is limited to supply reliability and physician familiarity in regions where the brand remains stocked.
• Pricing pressure is structural because bioequivalence standards allow generic substitution for tablets with equivalent strength and dosing.

What is the Orange Book status of Cytotec (misoprostol) and how does exclusivity typically work for this drug?

Cytotec is long past initial exclusivity and is not positioned as a sustained “brand exclusivity” asset. Generic competition for misoprostol generally proceeds through standard pathway approvals (ANDAs) based on bioequivalence, with ongoing generic releases typically governed by:

• The presence or absence of any still-listed patents for specific strengths, formulations, or approved labeling.
• The status of method-of-use coverage, where applicable.
• Patent expiry and any blocking listings in the Orange Book for the specific NDA and strength.

Featured snippet: exclusivity

• Misoprostol’s Cytotec-brand exclusivity is effectively exhausted, so market entry is driven by generic patent/label barriers rather than long-running brand exclusivity.

What patents protect misoprostol/Cytotec, and when do they expire?

A full, strength-by-strength patent landscape is not determinable from the provided input. Misoprostol’s core molecule and early formulation IP are generally expired across major jurisdictions, with any remaining patent coverage typically narrow:

• Specific formulation variants
• Specific dosing regimens for a defined claim set
• Manufacturing methods

Practical patent barrier profile

• For ulcer prevention, remaining barriers usually do not block generic tablets broadly.
• For obstetric and gynecologic uses, barriers more often relate to method-of-use claims, route, or dosing schedules, which may be harder to “design around” without changing labeling or clinical use assumptions.

What generic entry risks exist for Cytotec, and what would trigger new Paragraph IV filings?

For an off-patent molecule, risk is low that brand blocking will re-emerge from new chemical entity (NCE) IP. New Paragraph IV filings typically happen when:

• Specific formulation or manufacturing patents remain listed for a long tail period.
• A particular strength, packaging, or labeling revision triggers a new patent listing window.
• A company seeks to enter a market with an active “blocking” Orange Book listing.

Market impact of a “new entrant wave”

• In off-patent oral generics, additional entry typically compresses prices and shifts share toward the lowest-cost supply, unless the brand maintains preferred access contracts.

How does Cytotec misoprostol compare with PPIs for NSAID ulcer prevention?

Key comparative dynamics for commercial planning:

• PPIs typically offer superior ulcer prevention efficacy and are often better tolerated than misoprostol for chronic NSAID patients.
• Misoprostol remains used in patients where PPI use is unsuitable or where clinicians prefer a prostaglandin-based approach.
• Side-effect profile is the main differentiator. Misoprostol GI adverse events can limit adherence.

Implication for forecasts

• Misoprostol’s NSAID ulcer volume is likely stable to gently declining in markets with entrenched PPI adoption, unless safety, access, or guideline updates increase misoprostol share.

How does Cytotec perform in obstetric markets versus other uterotonics?

Misoprostol has an advantage profile that supports continued demand:

• Stability for storage and transport in resource-constrained settings.
• Flexible dosing approaches by route in obstetric protocols.
• Widely used in emergency and preventive strategies globally.

Implication

• Obstetric-related use can sustain misoprostol consumption even when NSAID-ulcer indication share softens.

What is the market size for misoprostol/Cytotec, and what are 2025–2035 projections?

Cytotec-branded sales are typically a small fraction of total misoprostol volumes in most markets because generics supply the majority of demand. Misoprostol overall demand tends to track:

• NSAID prescribing volumes for ulcer prevention.
• Guideline-driven gastroprotection choices (PPI vs misoprostol).
• Obstetric need and access programs.
• Public procurement and supply contracts.

Projection logic (directional, market-model based)

• NSAID ulcer prevention (developed markets): low-growth or declining trajectory due to PPI preference and reduced brand share.
• Obstetric/gynecologic (global): steadier demand with growth in access programs and continued use as standard-of-care in many protocols.
• Pricing: structurally declining under generic competition, with occasional stabilization tied to supply constraints.

Forecast outcome (high-level)

• Total misoprostol units: likely flat to modest growth globally through 2035, supported by obstetric utilization.
• Revenue for branded Cytotec: likely continues erosion, with the largest exposure in markets where brand contracts still exist.
• Wholesale value of the molecule: may grow slowly even if units rise, because price declines offset volume gains.

What regulatory factors affect Cytotec (misoprostol) availability and prescribing?

Regulatory controls that matter for commercialization and compliance:

• Pregnancy risk communication and distribution restrictions in certain jurisdictions.
• Labeling requirements and prescriber education programs for safety.
• Post-market pharmacovigilance for GI adverse events and obstetric misuse concerns.

Featured snippet: regulatory “pressure points”

• Misoprostol availability is typically stable, but prescriber behavior and labeling constraints can change utilization patterns.

What is the litigation and settlement landscape for Cytotec misoprostol generics?

A complete litigation map is not determinable from the provided input. In mature generic markets, litigation can include:

• ANDA patent litigation tied to any still-listed Orange Book patents.
• Product liability allegations related to misuse or adverse outcomes, especially in obstetric contexts.
• Regulatory disputes tied to labeling, distribution, or safety communications.

What manufacturing and IP barriers could slow generic competition for misoprostol tablets?

For generic tablet supply, the main barriers are operational rather than IP:

• Compliance with GMP for consistent dissolution and impurity profiles.
• API and excipient sourcing and scale economics.
• Quality system capacity and regulatory inspection outcomes.

Price effect

• When supply is constrained, prices can temporarily increase even in off-patent categories. Long-run, competition returns prices toward marginal-cost bands.

Where does Cytotec have the highest residual upside in 2025–2035?

Cytotec-branded upside is typically limited but can concentrate in:

• Markets with tender contracts or preferred formulary status for the brand.
• Regions where misoprostol is prescribed under specific branded pathways or where switching frictions remain.
• Obstetric procurement programs where brand continuity reduces stockouts and handling errors.

Key Takeaways

• Cytotec (misoprostol) is a mature, generic-dominated product; the near-term clinical trial landscape focuses on regimen optimization and comparative effectiveness rather than label-changing Cytotec-branded studies.
• Demand is split between NSAID ulcer gastroprotection (pressure from PPIs) and obstetric/gynecologic protocols (structural utilization).
• Market projections through 2035 favor stable to modest growth in total misoprostol use globally, with continued erosion of Cytotec-branded revenue due to substitution and pricing pressure.

FAQs

1. Is Cytotec still protected by patents in the US, and which Orange Book listings matter for misoprostol tablets?
2. Are there any Cytotec-specific Phase 3 trials that could expand labeling in 2025–2026?
3. How do misoprostol safety and tolerability compare with PPIs in NSAID ulcer prevention real-world use?
4. What drives misoprostol utilization growth in obstetric programs compared with other uterotonics?
5. What generic entry triggers typically cause misoprostol price spikes and subsequent reversals?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (misoprostol, Cytotec). U.S. Food and Drug Administration. (accessed via Orange Book database).